146 related articles for article (PubMed ID: 16800736)
21. Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells.
Ghosh MC; Grass L; Soosaipillai A; Sotiropoulou G; Diamandis EP
Tumour Biol; 2004; 25(4):193-9. PubMed ID: 15557757
[TBL] [Abstract][Full Text] [Related]
22. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries.
Matsumura M; Bhatt AS; Andress D; Clegg N; Takayama TK; Craik CS; Nelson PS
Prostate; 2005 Jan; 62(1):1-13. PubMed ID: 15389820
[TBL] [Abstract][Full Text] [Related]
23. Emerging interest in the kallikrein gene family for understanding and diagnosing cancer.
Sotiropoulou G; Rogakos V; Tsetsenis T; Pampalakis G; Zafiropoulos N; Simillides G; Yiotakis A; Diamandis EP
Oncol Res; 2003; 13(6-10):381-91. PubMed ID: 12725528
[TBL] [Abstract][Full Text] [Related]
24. Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors.
Magklara A; Mellati AA; Wasney GA; Little SP; Sotiropoulou G; Becker GW; Diamandis EP
Biochem Biophys Res Commun; 2003 Aug; 307(4):948-55. PubMed ID: 12878203
[TBL] [Abstract][Full Text] [Related]
25. Components of the kallikrein-kinin-system in patients with ARDS.
Fuhrer G; Heller W; Junginger W; Gröber O; Roth K
Prog Clin Biol Res; 1989; 308():737-42. PubMed ID: 2476827
[No Abstract] [Full Text] [Related]
26. Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation.
Bayés A; Tsetsenis T; Ventura S; Vendrell J; Aviles FX; Sotiropoulou G
Biol Chem; 2004 Jun; 385(6):517-24. PubMed ID: 15255184
[TBL] [Abstract][Full Text] [Related]
27. Inhibition profiles of human tissue kallikreins by serine protease inhibitors.
Luo LY; Jiang W
Biol Chem; 2006 Jun; 387(6):813-6. PubMed ID: 16800745
[TBL] [Abstract][Full Text] [Related]
28. Human tissue kallikrein 9: production of recombinant proteins and specific antibodies.
Memari N; Grass L; Nakamura T; Karakucuk I; Diamandis EP
Biol Chem; 2006 Jun; 387(6):733-40. PubMed ID: 16800734
[TBL] [Abstract][Full Text] [Related]
29. Activation and enzymatic characterization of recombinant human kallikrein 8.
Kishi T; Cloutier SM; Kündig C; Deperthes D; Diamandis EP
Biol Chem; 2006 Jun; 387(6):723-31. PubMed ID: 16800733
[TBL] [Abstract][Full Text] [Related]
30. The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids.
Yousef GM; Kapadia C; Polymeris ME; Borgono C; Hutchinson S; Wasney GA; Soosaipillai A; Diamandis EP
Biochim Biophys Acta; 2003 Jul; 1628(2):88-96. PubMed ID: 12890555
[TBL] [Abstract][Full Text] [Related]
31. Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry.
Obiezu CV; Soosaipillai A; Jung K; Stephan C; Scorilas A; Howarth DH; Diamandis EP
Clin Chem; 2002 Aug; 48(8):1232-40. PubMed ID: 12142379
[TBL] [Abstract][Full Text] [Related]
32. Functional proteomics of kallikrein-related peptidases in ovarian cancer ascites fluid.
Oikonomopoulou K; Batruch I; Smith CR; Soosaipillai A; Diamandis EP; Hollenberg MD
Biol Chem; 2010 Apr; 391(4):381-90. PubMed ID: 20180649
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells.
Prezas P; Arlt MJ; Viktorov P; Soosaipillai A; Holzscheiter L; Schmitt M; Talieri M; Diamandis EP; Krüger A; Magdolen V
Biol Chem; 2006 Jun; 387(6):807-11. PubMed ID: 16800744
[TBL] [Abstract][Full Text] [Related]
34. Role of urinary alpha1-antitrypsin in Padutin (kallikrein) inactivation.
Hörl WH; Schäfer RM; Heidland A
Eur J Clin Pharmacol; 1982; 22(6):541-4. PubMed ID: 6182004
[TBL] [Abstract][Full Text] [Related]
35. Dynamic role of kallikrein 6 in traumatic spinal cord injury.
Scarisbrick IA; Sabharwal P; Cruz H; Larsen N; Vandell AG; Blaber SI; Ameenuddin S; Papke LM; Fehlings MG; Reeves RK; Blaber M; Windebank AJ; Rodriguez M
Eur J Neurosci; 2006 Sep; 24(5):1457-69. PubMed ID: 16987227
[TBL] [Abstract][Full Text] [Related]
36. Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids.
Obiezu CV; Shan SJ; Soosaipillai A; Luo LY; Grass L; Sotiropoulou G; Petraki CD; Papanastasiou PA; Levesque MA; Diamandis EP
Clin Chem; 2005 Aug; 51(8):1432-42. PubMed ID: 15961548
[TBL] [Abstract][Full Text] [Related]
37. Extracellular proteases as targets for treatment of cancer metastases.
Lee M; Fridman R; Mobashery S
Chem Soc Rev; 2004 Sep; 33(7):401-9. PubMed ID: 15354221
[TBL] [Abstract][Full Text] [Related]
38. Complex formation between human kallikrein 13 and serum protease inhibitors.
Kapadia C; Yousef GM; Mellati AA; Magklara A; Wasney GA; Diamandis EP
Clin Chim Acta; 2004 Jan; 339(1-2):157-67. PubMed ID: 14687906
[TBL] [Abstract][Full Text] [Related]
39. Protease activation of alpha2-macroglobulin modulates a chaperone-like action with broad specificity.
French K; Yerbury JJ; Wilson MR
Biochemistry; 2008 Jan; 47(4):1176-85. PubMed ID: 18171086
[TBL] [Abstract][Full Text] [Related]
40. Mutant recombinant serpins as highly specific inhibitors of human kallikrein 14.
Felber LM; Kündig C; Borgoño CA; Chagas JR; Tasinato A; Jichlinski P; Gygi CM; Leisinger HJ; Diamandis EP; Deperthes D; Cloutier SM
FEBS J; 2006 Jun; 273(11):2505-14. PubMed ID: 16704423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
